The meaning of screening: detection of brain metastasis in the adjuvant setting for stage III melanoma

[1]  A. Lallas,et al.  European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. , 2022, European journal of cancer.

[2]  S. Sleijfer,et al.  Adjuvant treatment in patients with melanoma: The planning of scanning. , 2021, European journal of cancer.

[3]  D. Schadendorf,et al.  EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  M. Aboian,et al.  Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis , 2021, Journal of Neuro-Oncology.

[5]  B. Kiely,et al.  Scanxiety: a scoping review about scan-associated anxiety , 2021, BMJ Open.

[6]  M. Atkins,et al.  Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204) , 2021, Neuro-oncology.

[7]  D. Schadendorf,et al.  Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. , 2021, The Lancet. Oncology.

[8]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[9]  E. Balman,et al.  National Institute for Health and Care Excellence (NICE) , 2017, The Grants Register 2022.

[10]  M. Vernooij,et al.  The Impact of Incidental Findings Detected During Brain Imaging on Research Participants of the Rotterdam Study: An Interview Study , 2020, Cambridge quarterly of healthcare ethics : CQ : the international journal of healthcare ethics committees.

[11]  P. Ascierto,et al.  Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  M. Hendriks,et al.  Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[13]  J. D. de Groot,et al.  Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy , 2019, Annals of Surgical Oncology.

[14]  R. Ionescu-Ittu,et al.  Stage III melanoma incidence and impact of transitioning to the 8th AJCC staging system: a US population-based study. , 2019, Future oncology.

[15]  M. Atkins,et al.  Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain , 2018, The New England journal of medicine.

[16]  J. Gershenwald,et al.  The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care , 2018, Expert review of anticancer therapy.

[17]  J. Wilmott,et al.  Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. , 2018, The Lancet. Oncology.

[18]  D. Schadendorf,et al.  Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma , 2018, The New England journal of medicine.

[19]  A. Hauschild,et al.  Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma , 2017, The New England journal of medicine.

[20]  P. Ascierto,et al.  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma , 2017, The New England journal of medicine.

[21]  J. Malvehy,et al.  Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study. , 2016, Journal of the American Academy of Dermatology.

[22]  D. Kondziolka,et al.  Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. , 2011, Journal of neurosurgery.

[23]  Raymond Sawaya,et al.  Factors influencing the risk of local recurrence after resection of a single brain metastasis. , 2010, Journal of neurosurgery.

[24]  Claus Garbe,et al.  Melanoma epidemiology and trends. , 2009, Clinics in dermatology.

[25]  Jill S Barnholtz-Sloan,et al.  Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.